(Q58610647)

English

Efficacy of rituximab as a single-agent therapy for the treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency (CVID)

scientific article published on 05 November 2018

Statements

Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit